Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.60 EUR
Change Today +0.203 / 5.98%
Volume 0.0
LMW On Other Exchanges
As of 1:37 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (LMW) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/15/15 - €7.99
52 Week Low
10/1/15 - €2.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for XENOPORT INC (LMW)

xenoport inc (LMW) Related Businessweek News

No Related Businessweek News Found

xenoport inc (LMW) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

152 Employees
Last Reported Date: 02/27/15
Founded in 1999

xenoport inc (LMW) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $439.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $364.2K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $346.1K
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

xenoport inc (LMW) Key Developments

XenoPort, Inc. Announces Management Changes

XenoPort, Inc. announced a strategic shift to focus on and maximize the value of its commercial product, HORIZANT (gabapentin enacarbil) Extended Release Tablets. As part of this shift, XenoPort will discontinue development of XP23829 on its own and seek to partner this and other high potential development stage assets. In connection with the decision to focus on commercializing HORIZANT, Ronald W. Barrett, Ph.D., has retired as Chief Executive Officer and as a Director of XenoPort, effective immediately. Vincent J. Angotti, Executive Vice President and Chief Operating Officer, who has spearheaded the commercialization of HORIZANT, has been named Chief Executive Officer and has joined XenoPort’s Board of Directors. Dr. Barrett will continue to work with XenoPort in an advisory role, with a primary focus on ensuring a smooth transition and advising on potential partnering activities for the company’s development stage assets, including XP23829. Prior to joining XenoPort in May 2008, Mr. Angotti held several positions with Reliant Pharmaceuticals, Inc., the most recent of which was Senior Vice President of Sales and Marketing. Prior to Reliant, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, most recently as Executive Director, Field Operations. XenoPort also announced that John G. Freund, M.D., has been named Chairman of XenoPort’s Board of Directors. Dr. Freund has been a member of XenoPort’s Board since 1999 and has served as its Lead Independent Director since July 2008.

Xenoport, Inc. - Special Call

To discuss the preliminary top-line XP23829 Phase 2 clinical trial results

XenoPort, Inc. Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis

XenoPort, Inc. announced positive preliminary top-line results from its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. XP23829 met its primary endpoint in both 800 mg once daily and 400 mg twice daily doses, demonstrating statistically significant improvements in percent change from baseline to week 12 in Psoriasis Area and Severity Index (PASI) score. XP23829 is a patented prodrug of monomethyl fumarate (MMF) in a novel oral formulation that was designed to potentially offer physicians and patients an effective, better tolerated and easier to use therapeutic option to currently available fumarate products. Description of the Trial: This randomized, double-blind, placebo-controlled Phase 2 clinical trial of XP23829 was conducted in 33 sites in the United States in subjects with moderate-to-severe chronic plaque-type psoriasis. Two hundred eligible subjects were randomized to placebo or one of three treatment arms of XP23829: 400 mg or 800 mg once daily (QD) or 400 mg twice daily (BID). The 12-week treatment period included a three-week titration period followed by nine weeks of treatment at the targeted dose. There was a washout phase of up to four weeks prior to randomization for subjects who were previously taking systemic agents for the treatment of psoriasis. Treatment assignment was stratified based on prior biologic use and approximately 35% of randomized subjects had previous experience with biological treatments for their psoriasis. The primary endpoint of the study was the percent change from baseline to week 12 in PASI score. XP23829 was safe and generally well tolerated. There were no deaths or life-threatening adverse events. No subjects met the safety discontinuation criteria and the majority of treatment emergent adverse events were non-serious and mild or moderate in severity. Diarrhea adverse event rates were consistent with other drugs in the fumaric acid ester class ranging from 22% to 40% in the XP23829 treatment groups compared with 15% for placebo. Other treatment emergent adverse events occurring at an incident rate of greater than or equal to 10% were nausea, abdominal pain, vomiting and headache. The incidence of flushing in the XP23829 dose groups was similar to placebo. Gastrointestinal events were the most frequent adverse event leading to withdrawal during XP23829 treatment. There were two treatment emergent serious adverse events assessed as possibly related to treatment with XP23829: acute cholecystitis and enterocolitis. Both subjects recovered. No subjects experienced Grade 3 or Grade 4 lymphopenia. Less than 5% of subjects in any XP23829 treatment group reached Grade 2 lymphopenia and less than 15% reached Grade 1 at any visit. Lymphocyte levels in all subjects experiencing lymphopenia returned to within normal limits after treatment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMW:GR €3.60 EUR +0.203

LMW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $4.44 USD +0.22
Alkermes PLC $60.82 USD +0.92
Skyepharma PLC 339.50 GBp +0.50
Teva Pharmaceutical Industries Ltd $58.96 USD -0.28
Valeant Pharmaceuticals International Inc C$227.56 CAD +4.67
View Industry Companies

Industry Analysis


Industry Average

Valuation LMW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 4.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at